← Patent-cliff monitor Loss of exclusivity December 2038 latest FDA-listed patent expiry
Company UCB → View the full company profile on CliffBio Drug detail Brand name FINTEPLA Active ingredient FENFLURAMINE HYDROCHLORIDE Strength EQ 2.2MG BASE/ML Dosage form SOLUTION Route ORAL Modality Small molecule FDA approval June 2020 Marketing status RX
Listed patents Patent Expires Type 10452815*PED December 2038 — 10452815 June 2038 use U-2859 11406606*PED February 2038 — 10603290*PED February 2038 — 11786487*PED February 2038 — 11040018*PED February 2038 — 11759440*PED February 2038 — 11406606 August 2037 use U-3407 10603290 August 2037 use U-3347 11759440 August 2037 use U-3694 11040018 August 2037 use U-3347 11786487 August 2037 use U-3733 10947183*PED June 2037 — 10947183 December 2036 substance, product 9603814*PED November 2033 — 9603815*PED November 2033 — 9549909*PED November 2033 — 9610260*PED November 2033 — 10478442*PED November 2033 — 10478441*PED November 2033 — 12097206*PED November 2033 — 9603814 May 2033 use U-2858 10478441 May 2033 use U-2860 9603815 May 2033 use U-2858 9549909 May 2033 use U-2858 10478442 May 2033 use U-2860 9610260 May 2033 use U-2858 12097206 May 2033 use U-4013
Regulatory exclusivity Code Expires PED September 2029 ODE-393 March 2029 PED December 2027 ODE-312 June 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.